Harmony Biosciences Holdings (HRMY)

Return on assets (ROA)

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021
Net income (ttm)	US$ in thousands	145,493	122,625	114,993	137,702	128,853	150,755	200,237	189,468	181,468	155,673	58,110	48,696	34,597	11,675	23,204
Total assets	US$ in thousands	999,200	928,135	858,383	846,985	811,448	777,766	760,183	715,092	673,870	643,464	505,034	464,005	433,443	391,092	359,695
ROA		14.56%	13.21%	13.40%	16.26%	15.88%	19.38%	26.34%	26.50%	26.93%	24.19%	11.51%	10.49%	7.98%	2.99%	6.45%

December 31, 2024 calculation

ROA = Net income (ttm) ÷ Total assets
= $145,493K ÷ $999,200K
= 14.56%

Based on the provided data on Harmony Biosciences Holdings' return on assets (ROA) over multiple quarters, we can see fluctuations in the company's performance. The ROA figures show a general positive trend from June 30, 2021, to December 31, 2023, with the ROA increasing steadily from 6.45% to 26.50%.

However, there is a noticeable decline in ROA starting from June 30, 2023, where it fell to 19.38% and continued to decrease to 13.21% by September 30, 2024. This downward trend indicates a potential deterioration in the company's profitability in those quarters.

Although there was a slight improvement in ROA by December 31, 2024, reaching 14.56%, it is essential for investors and analysts to monitor the company's ROA closely to assess its ability to generate profits from its assets efficiently. fluctuations in ROA can be influenced by various factors, such as changes in revenue, expenses, asset utilization, or financial leverage, and require further investigation to understand the underlying reasons behind the shifts in profitability.